{"rows":[{"id":5670,"title":"Worsening suicidal ideation and prolonged adverse event following psilocybin administration in a clinical setting: case report and thematic analysis of one participant's experience.","authors":"Wahba M, Hayes C, Kletter M, McAllister-Williams RH","journal":"BJPsych open","publication_date":"2024-12-10","publication_year":2024,"doi":"10.1192/bjo.2024.768","pubmed_id":"39654264","openalex_id":"https://openalex.org/W4405215942","source_url":"https://pubmed.ncbi.nlm.nih.gov/39654264/","substance_tags":"psilocybin","topic_tags":"Depression,Clinical Trial,Case Report,Treatment-Resistant Depression,Adverse Events","study_type":"Clinical Trial","source_name":"PubMed","publication_status":"published","date_added":"2026-07-04 07:00:34","last_checked":"2026-08-09 08:28:05","bibtex":null,"source_record_id":"PMID:39654264","abstract_available":true,"abstract_source":"PubMed","abstract_source_url":"https://pubmed.ncbi.nlm.nih.gov/39654264/","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"PubMed","source_record_id":"PMID:39654264","source_url":"https://pubmed.ncbi.nlm.nih.gov/39654264/","doi":"10.1192/bjo.2024.768","pmid":"39654264","publication_date":"2024-12-10","importer_version":"2.1.3","text_redistributed":false}},{"id":3208,"title":"Psilocybin: the magic medicine for depression?","authors":"Corrigan A, Burchill E, Pelton L, Marrocu A, Mazzoleni A, Shackshaft L.","journal":"BJPsych open","publication_date":"2021-06-18","publication_year":2021,"doi":null,"pubmed_id":null,"openalex_id":null,"source_url":"https://europepmc.org/article/PMC/PMC8770735","substance_tags":"psilocybin","topic_tags":"Depression,Brain Imaging,Mechanism of Action,Default Mode Network,Aging,Personality Change,Emotional Processing,Review Article,Treatment-Resistant Depression,Safety","study_type":"Review Article","source_name":"Europe PMC","publication_status":"published","date_added":"2026-07-01 11:03:48","last_checked":"2026-08-09 08:15:11","bibtex":null,"source_record_id":"https://europepmc.org/article/PMC/PMC8770735","abstract_available":true,"abstract_source":"Europe PMC","abstract_source_url":"https://europepmc.org/article/PMC/PMC8770735","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"Europe PMC","source_record_id":"https://europepmc.org/article/PMC/PMC8770735","source_url":"https://europepmc.org/article/PMC/PMC8770735","doi":"","pmid":"","publication_date":"2021-06-18","importer_version":"2.1.3","text_redistributed":false}},{"id":1698,"title":"Effects of psilocybin versus escitalopram on rumination and thought suppression in depression.","authors":"Barba T, Buehler S, Kettner H, Radu C, Cunha BG, Nutt DJ, Erritzoe D, Roseman L, Carhart-Harris R","journal":"BJPsych open","publication_date":"2022-09-06","publication_year":2022,"doi":"10.1192/bjo.2022.565","pubmed_id":"36065128","openalex_id":"https://openalex.org/W4294808278","source_url":"https://pubmed.ncbi.nlm.nih.gov/36065128/","substance_tags":"psilocybin","topic_tags":"Depression,Mechanism of Action,Receptor Pharmacology,Clinical Trial,Randomized Controlled Trial,Drug Interactions","study_type":"Randomized Controlled Trial","source_name":"PubMed","publication_status":"published","date_added":"2026-07-01 06:48:05","last_checked":"2026-08-09 08:28:19","bibtex":null,"source_record_id":"PMID:36065128","abstract_available":true,"abstract_source":"PubMed","abstract_source_url":"https://pubmed.ncbi.nlm.nih.gov/36065128/","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"PubMed","source_record_id":"PMID:36065128","source_url":"https://pubmed.ncbi.nlm.nih.gov/36065128/","doi":"10.1192/bjo.2022.565","pmid":"36065128","publication_date":"2022-09-06","importer_version":"2.1.3","text_redistributed":false}},{"id":1427,"title":"Psilocybin for treatment-resistant depression without psychedelic effects: study protocol for a 4-week, double-blind, proof-of-concept randomised controlled trial.","authors":"Husain MI, Blumberger DM, Castle DJ, Ledwos N, Fellows E, Jones BDM, Ortiz A, Kloiber S, Wang W, Rosenblat JD, Mulsant BH","journal":"BJPsych open","publication_date":"2023-07-25","publication_year":2023,"doi":"10.1192/bjo.2023.535","pubmed_id":"37489299","openalex_id":"https://openalex.org/W4385230722","source_url":"https://pubmed.ncbi.nlm.nih.gov/37489299/","substance_tags":"psilocybin","topic_tags":"Depression,Receptor Pharmacology,Consciousness,Randomized Controlled Trial,Animal Study,Treatment-Resistant Depression,Safety,Adverse Events","study_type":"Randomized Controlled Trial","source_name":"PubMed","publication_status":"published","date_added":"2026-07-01 06:48:05","last_checked":"2026-08-09 08:28:14","bibtex":null,"source_record_id":"PMID:37489299","abstract_available":true,"abstract_source":"PubMed","abstract_source_url":"https://pubmed.ncbi.nlm.nih.gov/37489299/","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"PubMed","source_record_id":"PMID:37489299","source_url":"https://pubmed.ncbi.nlm.nih.gov/37489299/","doi":"10.1192/bjo.2023.535","pmid":"37489299","publication_date":"2023-07-25","importer_version":"2.1.3","text_redistributed":false}},{"id":449,"title":"Reporting of side-effects in clinical trials of psilocybin-assisted psychotherapy for psychiatric conditions: systematic review.","authors":"Marinis J, Clarke ST, Guerin AA, Guastella AJ, Bedi G","journal":"BJPsych open","publication_date":"2025-11-03","publication_year":2025,"doi":"10.1192/bjo.2025.10847","pubmed_id":"41178084","openalex_id":"https://openalex.org/W4415782096","source_url":"https://pubmed.ncbi.nlm.nih.gov/41178084/","substance_tags":"psilocybin","topic_tags":"Depression,Anxiety,PTSD,Clinical Trial,Randomized Controlled Trial,Systematic Review,Review Article,Safety,Adverse Events","study_type":"Randomized Controlled Trial","source_name":"PubMed","publication_status":"published","date_added":"2026-07-01 06:48:04","last_checked":"2026-08-09 08:27:55","bibtex":null,"source_record_id":"PMID:41178084","abstract_available":true,"abstract_source":"PubMed","abstract_source_url":"https://pubmed.ncbi.nlm.nih.gov/41178084/","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"PubMed","source_record_id":"PMID:41178084","source_url":"https://pubmed.ncbi.nlm.nih.gov/41178084/","doi":"10.1192/bjo.2025.10847","pmid":"41178084","publication_date":"2025-11-03","importer_version":"2.1.3","text_redistributed":false}},{"id":394,"title":"Psilocybin-assisted psychotherapy for treatment-resistant obsessive-compulsive disorder: protocol for an open-label pilot study.","authors":"Ledwos N, Baer J, Husain MI, Blumberger DM, Patterson R, Hollingdrake E, Cheung E, Hawco C, Zrenner C, Zrenner B, Feusner JD, Rossell SL, Castle DJ, Zai G","journal":"BJPsych open","publication_date":"2025-12-15","publication_year":2025,"doi":"10.1192/bjo.2025.10895","pubmed_id":"41392767","openalex_id":"https://openalex.org/W4417362478","source_url":"https://pubmed.ncbi.nlm.nih.gov/41392767/","substance_tags":"psilocybin","topic_tags":"OCD,Brain Imaging,Mechanism of Action,Receptor Pharmacology,Biomarkers,Aging,Clinical Trial,Randomized Controlled Trial,Safety","study_type":"Randomized Controlled Trial","source_name":"PubMed","publication_status":"published","date_added":"2026-07-01 06:48:04","last_checked":"2026-08-09 08:27:54","bibtex":null,"source_record_id":"PMID:41392767","abstract_available":true,"abstract_source":"PubMed","abstract_source_url":"https://pubmed.ncbi.nlm.nih.gov/41392767/","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"PubMed","source_record_id":"PMID:41392767","source_url":"https://pubmed.ncbi.nlm.nih.gov/41392767/","doi":"10.1192/bjo.2025.10895","pmid":"41392767","publication_date":"2025-12-15","importer_version":"2.1.3","text_redistributed":false}},{"id":269,"title":"Microdosing psilocybin for major depressive disorder: study protocol for a phase II double-blind placebo-controlled randomised partial crossover trial.","authors":"Beidas Z, Ragnhildstveit A, Blackman A, Anderson T, Fewster E, Syed OA, Sobolenko V, Kanca IK, Jaglinska M, Son T, Farb N, Petranker R","journal":"BJPsych open","publication_date":"2026-02-16","publication_year":2026,"doi":"10.1192/bjo.2025.10968","pubmed_id":"41693474","openalex_id":"https://openalex.org/W7129015437","source_url":"https://pubmed.ncbi.nlm.nih.gov/41693474/","substance_tags":"psilocybin","topic_tags":"Depression,Microdosing,Wellbeing,Creativity,Clinical Trial,Randomized Controlled Trial,Review Article,Observational Study,Safety","study_type":"Randomized Controlled Trial","source_name":"PubMed","publication_status":"published","date_added":"2026-06-30 22:38:07","last_checked":"2026-08-09 08:27:52","bibtex":null,"source_record_id":"PMID:41693474","abstract_available":true,"abstract_source":"PubMed","abstract_source_url":"https://pubmed.ncbi.nlm.nih.gov/41693474/","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"PubMed","source_record_id":"PMID:41693474","source_url":"https://pubmed.ncbi.nlm.nih.gov/41693474/","doi":"10.1192/bjo.2025.10968","pmid":"41693474","publication_date":"2026-02-16","importer_version":"2.1.3","text_redistributed":false}}],"total":7,"page":1,"per_page":20,"pages":1,"resource":"papers","filters":{"q":null,"author":null,"substances":["psilocybin","psilocin"],"topic":null,"study_type":null,"cited_doi":null,"sources":[],"publication_statuses":[],"year":null,"journal":"BJPsych open","from":null,"to":null,"added_from":null,"added_to":null,"sort":"newly_added","page":1,"per_page":"20"}}